Hematologic Malignancies

Beta-blockers May Improve Survival in Multiple Myeloma

Beta-blockers May Improve Survival in Multiple Myeloma

By

Administration of beta blockers in patients with newly diagnosed multiple myeloma may be associated with a reduced risk of cancer-specific death.

Thalidomide, Lenalidomide Equivalent With Respect to Survival in Myeloma

Thalidomide, Lenalidomide Equivalent With Respect to Survival in Myeloma

By

Thalidomide and lenalidomide are equivalent with respect to survival outcomes in patients with multiple myeloma.

FDA Approves Daratumumab Regimens for Relapsed Multiple Myeloma

FDA Approves Daratumumab Regimens for Relapsed Multiple Myeloma

By

The US FDA has granted approval for additional indications for daratumumab for the treatment of patients with multiple myeloma who have received prior therapies.

Overall Risk of Second Primary Malignancies is Low in Multiple Myeloma

Overall Risk of Second Primary Malignancies is Low in Multiple Myeloma

By

A panel of International Myeloma Working Group members  presents their review of current data on the potential host-, disease-, and treatment-related risk factors associated with the development of second primary malignancies in patients with multiple myeloma.

Vorinostat + Len-Dex Active in Lenalidomide-refractory Patients With Multiple Myeloma

Vorinostat + Len-Dex Active in Lenalidomide-refractory Patients With Multiple Myeloma

By

In this single-center, open-label, phase 2b trial, researchers determined if adding vorinostat to lenadolimide and dexamethasome would improve outcomes for patients with multiple myeloma refractory to lenalidomide.

Fecal Occult Blood Test, Colonoscopy Useful for Detecting Dasatinib-induced Colitis

Fecal Occult Blood Test, Colonoscopy Useful for Detecting Dasatinib-induced Colitis

By

Researchers examined the frequency of TKI-induced hemorrhagic colitis among patients with CML treated with dasatinib and evaluated the efficacy of screening with a fecal occult blood test followed by colonoscopy in this patient population.

Lipid-lowering Drugs May Confer Survival Benefit in Chronic Lymphocytic Leukemia

Lipid-lowering Drugs May Confer Survival Benefit in Chronic Lymphocytic Leukemia

By

Abnormal lipid metabolism is observed in patients with CLL, prompting an investigation to determine if prevalence of metabolic syndrome is higher in patients with CLL and whether lipid-lowering medications impact survival.

Panobinostat, Bortezomib, Thalidomide Efficacious in Relapsed Myeloma

By

In this study, researchers sought to improve the safety of panobinostat plus bortezomib and dexamethasone for relapsed or relapsed and refractory multiple myeloma.

'Just Bag It' Campaign Aims to Promote Safe Vincristine Handling

'Just Bag It' Campaign Aims to Promote Safe Vincristine Handling

By

The NCCN campaign was developed to ensure the proper administration of vincristine and to render it impossible to accidentally administer the medication into the spinal fluid.

ROR1 Expression May Enhance Disease Progression in CLL

ROR1 Expression May Enhance Disease Progression in CLL

By

Expression of ROR1 could promote leukemia-cell activation and enhance disease progression in patients with chronic lymphocytic leukemia, according to a study.

Ibrutinib Effective as Salvage Therapy in Relapsed CLL Following Allogeneic HSCT

Ibrutinib Effective as Salvage Therapy in Relapsed CLL Following Allogeneic HSCT

By

A report of an evaluation of the benefit of ibrutinib in relapsed CLL following allogeneic HSCT based on an analysis of data from patients with relapsed CLL who received ibrutinib salvage therapy after allogeneic HSCT.

Treatment Facility Volume Associated With Mortality Risk in Multiple Myeloma

Treatment Facility Volume Associated With Mortality Risk in Multiple Myeloma

By

Results of this data analysis demonstrate the relationship between treatment facility volume and all-cause mortality among patients with multiple myeloma.

Study Identifies Factors Associated With Infection-related Complications in ALL

Study Identifies Factors Associated With Infection-related Complications in ALL

By

Data on neutropenia and infection-related complications in patients with ALL are lacking; therefore, this study focused on identifying the characteristics and risk factors of infection-related complications in children with newly diagnosed ALL.

Levofloxacin Prophylaxis May Reduce Infection Rate in Relapsed/Refractory AML

Levofloxacin Prophylaxis May Reduce Infection Rate in Relapsed/Refractory AML

By

This study evaluated whether antibacterial prophylaxis effectively reduced the rate of infections overall for patients receiving intensive chemotherapy for relapsed/refractory AML.

Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

By

Frontline treatment with rituximab plus high-dose sequential chemotherapy with autologous HSCT failed to improve progression-free or overall survival compared with R-CHOP in patients with diffuse large B-cell lymphoma.

Daratumumab With Len-Dex Prolongs PFS in R/R Multiple Myeloma

Daratumumab With Len-Dex Prolongs PFS in R/R Multiple Myeloma

By

Adding daratumumab to lenalidomide and dexamethasone significantly prolonged progression-free survival compared with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.

Severe Fatigue Associated With Unemployment in Hodgkin Lymphoma Survivors

Severe Fatigue Associated With Unemployment in Hodgkin Lymphoma Survivors

By

Severe fatigue is associated with unemployment and financial problems in survivors of Hodgkin lymphoma, highlighting the need for clinicians to address fatigue in these patients.

Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera

Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera

By

Ruxolitinib is an effective long-term treatment option for patients with polycythemia resistant or intolerant to hydroxyurea, according to a study presented at the 2016 European Hematology Association Congress.

Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response

Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response

By

In patients with chronic myeloid leukemia in chronic phase, prolonged treatment with imatinib helps to achieve a deeper molecular response over 5 years.

Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera

Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera

[Blood and Lymphatic Cancer: Targets and Therapy] This research provides a summary of the pathobiology of polycythemia vera, and examines challenges associated with traditional PV treatment options and the clinical data for ruxolitinib.

Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera

Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera

By

High platelet counts and hemoglobin/hematocrit levels may be associated with hearing loss in patients with polycythemia vera.

Study Assesses Risk of Secondary AML in Patients With Myeloproliferative Neoplasms

Study Assesses Risk of Secondary AML in Patients With Myeloproliferative Neoplasms

By

Among patients with myeloproliferative neoplasms, men with primary myelofibrosis diagnosed after 2006 are at the highest risk of developing secondary acute myeloid leukemia (AML).

Carmustine Infusion Reactions Occur Despite Extending Infusion Duration

Carmustine Infusion Reactions Occur Despite Extending Infusion Duration

By

Infusion reactions during administration of high-dose carmustine as part of the BEAM conditioning regimen are common and do not appear to be reduced by modestly extending the duration of infusion or giving premedications.

Cancer-related Fatigue Common in Hodgkin Lymphoma Survivors

Cancer-related Fatigue Common in Hodgkin Lymphoma Survivors

By

There is a high incidence of severe acute and persistent cancer-related fatigue in survivors of Hodgkin lymphoma, regardless of tumor stage or treatment.

Daratumumab Combo Improves PFS in Relapsed/Refractory Myeloma

Daratumumab Combo Improves PFS in Relapsed/Refractory Myeloma

By

Daratumumab plus bortezomib and dexamethasone improves progression-free survival in multiple myeloma.

Daratumumab Plus Len-Dex an Encouraging Combo for Multiple Myeloma

Daratumumab Plus Len-Dex an Encouraging Combo for Multiple Myeloma

By

Daratumumab plus lenalidomide and dexamethasone resulted in rapid, deep, durable responses in patients with multiple myeloma.

SES Factors Impact Survival of Younger Patients With Myeloma

SES Factors Impact Survival of Younger Patients With Myeloma

By

Sociodemographic factors, not race or ethnicity, impact survival of younger patients with multiple myeloma.

CML-CP: Dasatinib, Nilotinib Associated With Similar Survival Outcomes as Frontline Therapy

CML-CP: Dasatinib, Nilotinib Associated With Similar Survival Outcomes as Frontline Therapy

By

Dasatinib and nilotinib are associated with similar response rates and survival outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).

Ipilumumab Feasible for Recurrent Hematologic Cancers After Allogeneic Stem Cell Transplant

Ipilumumab Feasible for Recurrent Hematologic Cancers After Allogeneic Stem Cell Transplant

By

Repeat doses of ipilimumab can restore a complete remission in patients with advanced blood cancers who relapse after allogeneic hematopoietic stem cell transplant (alloHSCT).

Social Support Crucial for Patients With CML Receiving Lifelong Targeted Therapy

Social Support Crucial for Patients With CML Receiving Lifelong Targeted Therapy

By

For patients with chronic myeloid leukemia treated with lifelong targeted therapies, social support is crucial for maintaining psychological well-being.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs